잠시만 기다려 주세요. 로딩중입니다.

RUNX1 Dosage in Development and Cancer

Molecules and Cells 2020년 43권 2호 p.126 ~ 138
 ( Lie-a-ling Michael ) - University of Manchester Cancer Research UK Manchester Institute

 ( Mevel Renaud ) - University of Manchester Cancer Research UK Manchester Institute
 ( Patel Rahima ) - University of Manchester Cancer Research UK Manchester Institute
 ( Blyth Karen ) - Cancer Research UK Beatson Institute
 ( Baena Esther ) - University of Manchester Cancer Research UK Manchester Institute
 ( Kouskoff Valerie ) - University of Manchester Division of Developmental Biology and Medicine
 ( Lacaud Georges ) - University of Manchester Cancer Research UK Manchester Institute

Abstract


The transcription factor RUNX1 first came to prominence due to its involvement in the t(8;21) translocation in acute myeloid leukemia (AML). Since this discovery, RUNX1 has been shown to play important roles not only in leukemia but also in the ontogeny of the normal hematopoietic system. Although it is currently still challenging to fully assess the different parameters regulating RUNX1 dosage, it has become clear that the dose of RUNX1 can greatly affect both leukemia and normal hematopoietic development. It is also becoming evident that varying levels of RUNX1 expression can be used as markers of tumor progression not only in the hematopoietic system, but also in non-hematopoietic cancers. Here, we provide an overview of the current knowledge of the effects of RUNX1 dosage in normal development of both hematopoietic and epithelial tissues and their associated cancers.

키워드

development; dosage; hematopoiesis; runx1; tumorigenesis
원문 및 링크아웃 정보
 
등재저널 정보